{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:03:55Z","timestamp":1780517035157,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euros.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:37:34Z","timestamp":1771623454000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Incidental Prostate Cancer Is an Uncommon but Clinically Non-negligible Cause of Death in Selected Long-term Survivors of Urothelial Carcinoma\u2014Oncological Outcomes and a Proposed Follow-up Strategy from a Tertiary Referral Center"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-6799","authenticated-orcid":false,"given":"Marc A.","family":"Furrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lyttwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"P\u00e4rli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona C.","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wuethrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall M.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.02.004_b0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.juro.2016.08.088","article-title":"Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients","volume":"197","author":"Fahmy","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.004_b0010","doi-asserted-by":"crossref","first-page":"848.e17","DOI":"10.1016\/j.urolonc.2020.05.018","article-title":"Long-term outcomes of incidental prostate cancer at radical cystectomy","volume":"38","author":"Packiam","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.004_b0015","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.ejso.2017.08.013","article-title":"Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: results from an international retrospective study","volume":"43","author":"Malte","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euros.2026.02.004_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21681805.2018.1534885","article-title":"The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis","volume":"52","author":"J\u00f8nck","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euros.2026.02.004_b0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bju.15579","article-title":"A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer","volume":"130","author":"Furrer","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.004_b0030","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.euf.2020.09.016","article-title":"Routine preoperative bone scintigraphy has limited impact on the management of patients with invasive bladder cancer","volume":"7","author":"Furrer","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.02.004_b0035","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bju.14123","article-title":"Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time","volume":"121","author":"Furrer","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.004_b0040","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.02.004_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prnil.2016.06.002","article-title":"Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival","volume":"4","author":"Kaelberer","year":"2016","journal-title":"Prostate Int"},{"key":"10.1016\/j.euros.2026.02.004_b0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.02.004_b0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.004_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.004_b0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.004_b0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.004_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"van der Heijden","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.euros.2026.02.004_b0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.euf.2025.02.005","article-title":"Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: a phase 2 trial\u2014results of secondary endpoints","volume":"11","author":"Verghote","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.02.004_b0085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.004_b0090","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bju.16598","article-title":"In-field prostate cancer recurrence following radical prostatectomy and salvage radiation","volume":"135","author":"Martin","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.004_b0095","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euros.2026.02.004_b0100","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2026.02.004_b0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.004_b0110","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.02.004_b0115","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:25:55Z","timestamp":1774869955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"alternative-id":["S2666168326000364"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidental Prostate Cancer Is an Uncommon but Clinically Non-negligible Cause of Death in Selected Long-term Survivors of Urothelial Carcinoma\u2014Oncological Outcomes and a Proposed Follow-up Strategy from a Tertiary Referral Center","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}